Nektar Therapeutics said a jury awarded it $90 million, plus interest, after finding that Eli Lilly breached an implied covenant of good faith and fair dealing in a co-development agreement tied to rezpegaldesleukin (rezpeg). Despite the legal win, shares were viewed cautiously by investors because the verdict fell short of Nektar’s $1 billion ask and did not translate into an immediate damage windfall.